1[1]Pruss T P,Stroissing H,Radhofer W S,et al.Overview of the pharmacological properties,pharmacokinetics and animal safety assessment of lornoxicam[J].Postgrad.Med.J,1990,66:Suppl.4,18
2[2]Urano H,Itoga H,Fukushima K,et al.Disposition of lornoxicam (2)-tissue distribution, foeto-placental transfer and tranfer into milk after single administration to rats[J].Kiso To Rinsho,1997,31(4):21
3[3]Hitzenberger G,Radhofer Welte S,Takacs F,et al.Pharmacokinetics of lornoxicam in man[J].Postgrad.Med.J,1990,66:Suppl.4,22
4[4]Turner P,Johnston-A.Clinical pharmacokinetic studies with lornoxicam[J].Postgrad.Med.J,1990,66:Suppl.4,28
5[5]Atzpodien E,Mehdi N,Clarke D,et al.Subacute and chronic oral toxicity of lornoxicam in cynomolgus monkeys[J].Food-Chem-Toxocol,1997,35:ISS 5,465
6[6]Pohlmeyer E G,Mehdi N,Clarke D,et al.Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rat[J].Food-Chem-Toxocol,1997,35:ISS 9,909
7[7]Rosenow DE,van Krieken F,Stolke D,et al.Intravenous administration of lornoxicam,a new NSAID,and pethidine for postoperation pain[J].Clin Drug Invest,1996,11(1):11
8[8]Balfour JA,Fitton A,Barradell LB.Lornixicam:A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions[J].Drugs,1996,51(Apr):639
9[9]Radhofer W S,Rabasseda.Lornoxicam,a new potent NSAID with an improved tolerability profile[J].Drugs of Today,2000,36(1):55
10[10]Berry H,Bird HA,Black C,et al.A double blind,multicentre,placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee[J].Ann Rheum Dis,1992,51:238
